Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...
Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...
The East New Britain Provincial Assembly held a special sitting today, Friday, March 14, 2025, at the Degenhardt Conference Centre in Vunapope to pay their last respects and to honor one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback